RxDoctor Payments Data

Manan Sampat

Ophthalmology · Danville, KYNPI 1336503820

Payments from drug & device makers

$748in general payments, 2019–2025

Across 23 payments — averaging $32.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$329
  • Omeros Corporation$118
  • AbbVie$60
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$39
  • Aerie Pharmaceuticals, Inc.$37
  • Novartis$36
  • plus $130 from 6 others

What the payments were for

  • Food & beverage$72997%
  • Gifts$193%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$748 in reported general payments places this provider in the 35th percentile of 216 ophthalmology providers in Kentucky.

See all ophthalmology providers in Kentucky

Medicare billing

Part B allowed, 2024
$208,357
Medicare patients
644
Services billed
1,957

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost103$39,990
RestasisCyclosporine34$29,386
XiidraLifitegrast16$22,463
Prednisolone Acetate504$14,606
Cyclosporine16$9,277
CombiganBrimonidine Tartrate/Timolol38$8,935
RocklatanNetarsudil Mesylat/Latanoprost18$8,662
Ketorolac Tromethamine457$6,901
Travoprost11$6,118
Brimonidine Tartrate51$5,888
Latanoprost623$5,783
Timolol Maleate141$5,557
Ofloxacin504$5,500
ErythromycinErythromycin Base321$3,669
SimbrinzaBrinzolamide/Brimonidine Tart15$3,403

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$60$78,311175 claims
Bausch & Lomb Americas Inc.Xiidra$24$22,46316 claims
Aerie Pharmaceuticals, Inc.Rocklatan$37$8,66218 claims
AlconSimbrinza$329$3,40315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 216 ophthalmology providers in Kentucky.

Other ophthalmology in Danville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →